Evidence map›Paper›PMID 39457651›Full record

ArticleBiomedicines2024

Blast Transformation of Chronic Myeloid Leukemia Driven by Acquisition of t(8;21)(q22;q22)/

Adolfo Fernández-Sánchez, Alberto Hernández-Sánchez, Cristina De Ramón, María-Carmen Chillón, María Belén Vidriales, Mónica Baile-González, Cristina-Teresa Fuentes-Morales, Magdalena Sierra-Pacho, Lucía López-Corral, Fermín Sánchez-Guijo

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Adolfo Fernández-SánchezHematology Department, IBSAL-University Hospital of Salamanca, Department of Medicine and Cancer Research Center (CIC), University of Salamanca, 37007 Salamanca, Spain.
Alberto Hernández-SánchezHematology Department, IBSAL-University Hospital of Salamanca, Department of Medicine and Cancer Research Center (CIC), University of Salamanca, 37007 Salamanca, Spain.ORCID 0000-0002-6601-3096
Cristina De RamónHematology Department, IBSAL-University Hospital of Salamanca, Department of Medicine and Cancer Research Center (CIC), University of Salamanca, 37007 Salamanca, Spain.ORCID 0000-0002-8167-6410
María-Carmen ChillónHematology Department, IBSAL-University Hospital of Salamanca, Department of Medicine and Cancer Research Center (CIC), University of Salamanca, 37007 Salamanca, Spain.
María Belén VidrialesHematology Department, IBSAL-University Hospital of Salamanca, Department of Medicine and Cancer Research Center (CIC), University of Salamanca, 37007 Salamanca, Spain.
Mónica Baile-GonzálezHematology Department, IBSAL-University Hospital of Salamanca, Department of Medicine and Cancer Research Center (CIC), University of Salamanca, 37007 Salamanca, Spain.
Cristina-Teresa Fuentes-MoralesHematology Department, IBSAL-University Hospital of Salamanca, Department of Medicine and Cancer Research Center (CIC), University of Salamanca, 37007 Salamanca, Spain.
Magdalena Sierra-PachoHematology Department, IBSAL-University Hospital of Salamanca, Department of Medicine and Cancer Research Center (CIC), University of Salamanca, 37007 Salamanca, Spain.ORCID 0000-0001-7208-1362
Lucía López-CorralHematology Department, IBSAL-University Hospital of Salamanca, Department of Medicine and Cancer Research Center (CIC), University of Salamanca, 37007 Salamanca, Spain.
Fermín Sánchez-GuijoHematology Department, IBSAL-University Hospital of Salamanca, Department of Medicine and Cancer Research Center (CIC), University of Salamanca, 37007 Salamanca, Spain.ORCID 0000-0002-7076-7739

Funding

Instituto de Salud Carlos III CM23/00101
6 · The paper itself

Abstract

The advent of tyrosine kinase inhibitors (TKIs) has changed the natural history of chronic myeloid leukemia (CML), and the transformation from the chronic phase to the blast phase (BP) is currently an uncommon situation. However, it is one of the major remaining challenges in the management of this disease, as it is associated with dismal outcomes. We report the case of a 63-year-old woman with a history of CML with poor response to imatinib who progressed to myeloid BP-CML, driven by the acquisition of t(8;21)(q22;q22)/

Indexed as

blast phasechronic myeloid leukemiacore binding factor rearrangementT315I mutation

Identifiers

PMID39457651
PMCPMC11504412

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.